Original Articles
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jan 28, 2009; 15(4): 431-440
Published online Jan 28, 2009. doi: 10.3748/wjg.15.431
Figure 8
Figure 8 FCM showing lower P-gp expression in HepG2 cells (A) and HepG2/mdr1-shRNA (B) in test groups than in control groups (65% vs 94. 1%, P < 0.05). There was no significant difference between groups treated with in situ injection and intra-abdominal injection of pSUPER-mdr1 (65.1% vs 58.7%).